NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

胃癌:開發中產品分析

Gastric Cancer (Oncology) - Drugs In Development, 2021

出版商 Global Markets Direct 商品編碼 232773
出版日期 內容資訊 英文 3373 Pages
訂單完成後即時交付
價格
胃癌:開發中產品分析 Gastric Cancer (Oncology) - Drugs In Development, 2021
出版日期: 2021年08月30日內容資訊: 英文 3373 Pages
簡介

胃癌是胃內膜發生的惡性腫瘤,其徵兆及症狀有倦怠感,腹痛,嘔吐,體重減少,飯後的飽漲感,胃部發熱,消化不良等。罹患胃癌的原因有抽煙、惡性貧血、胃部息肉、感染胃幽門桿菌,家族病史等。

本報告提供胃癌治療藥的開發中產品概要和臨床實驗的各階段產品概要,提供您主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

胃癌 - 概要

胃癌 - 治療藥的開發

胃癌 - 治療藥的評估

胃癌的治療藥開發企業

藥物簡介

胃癌 - 暫停中的計劃

胃癌 - 開發中止的產品

胃癌 - 產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC13043IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Drugs In Development, 2021, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 23, 180, 223, 5, 26, 202, 42 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 12, 10, 1, 1, 9 and 3 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Gastric Cancer - Overview
  • Gastric Cancer - Therapeutics Development
  • Gastric Cancer - Therapeutics Assessment
  • Gastric Cancer - Companies Involved in Therapeutics Development
  • Gastric Cancer - Drug Profiles
  • Gastric Cancer - Dormant Projects
  • Gastric Cancer - Discontinued Products
  • Gastric Cancer - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Gastric Cancer, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Gastric Cancer - Pipeline by 3SBio Inc, 2021
  • Gastric Cancer - Pipeline by AbbVie Inc, 2021
  • Gastric Cancer - Pipeline by Abclon Inc, 2021
  • Gastric Cancer - Pipeline by Abion Inc, 2021
  • Gastric Cancer - Pipeline by ABL Bio Inc, 2021
  • Gastric Cancer - Pipeline by Abpro Corp, 2021
  • Gastric Cancer - Pipeline by AbTis Co Ltd, 2021
  • Gastric Cancer - Pipeline by Accurus Biosciences Inc, 2021
  • Gastric Cancer - Pipeline by Acrotech Biopharma LLC, 2021
  • Gastric Cancer - Pipeline by AD Pharmaceuticals Co Ltd, 2021
  • Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, 2021
  • Gastric Cancer - Pipeline by ADC Therapeutics SA, 2021
  • Gastric Cancer - Pipeline by Advenchen Laboratories LLC, 2021
  • Gastric Cancer - Pipeline by Affimed GmbH, 2021
  • Gastric Cancer - Pipeline by AffyImmune Therapeutics Inc, 2021
  • Gastric Cancer - Pipeline by Agenus Inc, 2021
  • Gastric Cancer - Pipeline by AIMM Therapeutics BV, 2021
  • Gastric Cancer - Pipeline by Akeso Inc, 2021
  • Gastric Cancer - Pipeline by Alkermes Plc, 2021
  • Gastric Cancer - Pipeline by Alligator Bioscience AB, 2021
  • Gastric Cancer - Pipeline by Alphamab Oncology, 2021
  • Gastric Cancer - Pipeline by Alteogen Inc, 2021
  • Gastric Cancer - Pipeline by AltruBio Inc, 2021
  • Gastric Cancer - Pipeline by ALX Oncology Holdings Inc, 2021
  • Gastric Cancer - Pipeline by Ambrx Biopharma Inc, 2021
  • Gastric Cancer - Pipeline by amcure GmbH, 2021
  • Gastric Cancer - Pipeline by Amgen Inc, 2021
  • Gastric Cancer - Pipeline by Andes Biotechnologies, 2021
  • Gastric Cancer - Pipeline by Anew Oncology Inc, 2021
  • Gastric Cancer - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, 2021
  • Gastric Cancer - Pipeline by Antikor Biopharma Ltd, 2021
  • Gastric Cancer - Pipeline by Apollomics Inc, 2021
  • Gastric Cancer - Pipeline by Apotex Inc, 2021
  • Gastric Cancer - Pipeline by Aprea Therapeutics Inc, 2021
  • Gastric Cancer - Pipeline by Arbele Ltd, 2021
  • Gastric Cancer - Pipeline by Arcus Biosciences Inc, 2021
  • Gastric Cancer - Pipeline by Argonaut Therapeutics Ltd, 2021
  • Gastric Cancer - Pipeline by Arog Pharmaceuticals Inc, 2021
  • Gastric Cancer - Pipeline by Arromax Pharmatech Co Ltd, 2021
  • Gastric Cancer - Pipeline by Aryogen Pharmed, 2021
  • Gastric Cancer - Pipeline by Immunicum AB, 2021
  • Gastric Cancer - Pipeline by Immunisbio Co Ltd, 2021
  • Gastric Cancer - Pipeline by ImmunityBio Inc, 2021
  • Gastric Cancer - Pipeline by Immunocore Holdings Plc, 2021
  • Gastric Cancer - Pipeline by Immunomet Therapeutics Inc, 2021
  • Gastric Cancer - Pipeline by Immunomic Therapeutics Inc, 2021
  • Gastric Cancer - Pipeline by Immunotech Biopharm Ltd, 2021
  • Gastric Cancer - Pipeline by Imugene Ltd, 2021
  • Gastric Cancer - Pipeline by Incyte Corp, 2021
  • Gastric Cancer - Pipeline by Inhibrx Inc, 2021
  • Gastric Cancer - Pipeline by Inner Mongolia Qite Biotechnology (Group) Co Ltd, 2021
  • Gastric Cancer - Pipeline by Innovative Cellular Therapeutics Co Ltd, 2021
  • Gastric Cancer - Pipeline by Innovent Biologics Inc, 2021
  • Gastric Cancer - Pipeline by Inovio Pharmaceuticals Inc, 2021
  • Gastric Cancer - Pipeline by Intocell Inc, 2021
  • Gastric Cancer - Pipeline by Intra-Immusg Pvt Ltd, 2021
  • Gastric Cancer - Pipeline by InxMed Shanghai Co Ltd, 2021
  • Gastric Cancer - Pipeline by Ipsen SA, 2021
  • Gastric Cancer - Pipeline by Istari Oncology Inc, 2021
  • Gastric Cancer - Pipeline by Ithax Pharmaceuticals Inc, 2021
  • Gastric Cancer - Pipeline by JenKem Technology Co Ltd, 2021
  • Gastric Cancer - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2021
  • Gastric Cancer - Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, 2021
  • Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
  • Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, 2021
  • Gastric Cancer - Pipeline by Jina Pharmaceuticals Inc, 2021
  • Gastric Cancer - Pipeline by Jiuzhitang Co Ltd, 2021
  • Gastric Cancer - Pipeline by Johnson & Johnson, 2021
  • Gastric Cancer - Pipeline by Joint Biosciences Ltd, 2021
  • Gastric Cancer - Pipeline by Jounce Therapeutics Inc, 2021
  • Gastric Cancer - Pipeline by JW Pharmaceutical Corp, 2021
  • Gastric Cancer - Pipeline by Karyo Biologics LLC, 2021
  • Gastric Cancer - Pipeline by Karyopharm Therapeutics Inc, 2021
  • Gastric Cancer - Pipeline by KeyMed Biosciences Inc, 2021
  • Gastric Cancer - Pipeline by Keythera Pharmaceuticals Co Ltd, 2021
  • Gastric Cancer - Pipeline by Kintor Pharmaceutical Ltd, 2021
  • Gastric Cancer - Pipeline by KLUS Pharma Inc, 2021
  • Gastric Cancer - Pipeline by Komipharm International Co Ltd, 2021
  • Gastric Cancer - Pipeline by Kringle Pharma Inc, 2021
  • Gastric Cancer - Pipeline by Kupffer Biotherapeutics Inc, 2021
  • Gastric Cancer - Pipeline by Kymab Ltd, 2021
  • Gastric Cancer - Pipeline by Kyowa Kirin Co Ltd, 2021
  • Gastric Cancer - Pipeline by LaNova Medicines Ltd, 2021
  • Gastric Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, 2021
  • Gastric Cancer - Pipeline by Lead Discovery Center GmbH, 2021
  • Gastric Cancer - Pipeline by Leap Therapeutics Inc, 2021
  • Gastric Cancer - Pipeline by Turnstone Biologics Inc, 2021
  • Gastric Cancer - Pipeline by Tvardi Therapeutics Inc, 2021

List of Figures

List of Figures

  • Number of Products under Development for Gastric Cancer, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021